Notably, we observed that the activation levels of MAIT cells in severe cases were lower than those in moderate and convalescent cases, which conflicts with the results other studies that identified MAIT cells with high expression of the CD69 activation marker being associated with poor clinical outcome and disease severity in patients with COVID-19 (25, 26). This evidence concerns the gene CD69 and COVID-19.